Patient Experience
Early clinical experience with dalbavancin in a tertiary hospital in Madrid, Spain
Data from a subgroup of ABSSSI patients only – from a retrospective study including all adult patients who received at least 1 dose of DAL from January 2016 to November 2016 at our institution2